This topic contains 0 replies, has 1 voice, and was last updated by  MS News Today Moderator 8 months, 1 week ago.

  • Author
    Posts
  • #16980
     MS News Today Moderator 
    Participant

    Two-year treatment with temelimab reduced brain atrophy, or shrinkage, preserved myelin, and reduced disease progression in patients with relapsing-remitting multiple sclerosis (RRMS), according to findings from an extension study of a Phase 2b clinical trial. Click here to learn more about this trial and its findings.

    Are you interested in more news about this treatment for RRMS?

You must be logged in to reply to this topic.

Copyright © 2017-2019 All rights reserved.

©2019 KLEO Template a premium and multipurpose theme from Seventh Queen

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending
or

Log in with your credentials

or    

Forgot your details?

or

Create Account